Correspondence 0001104659-24-031034 from Apogee Therapeutics, Inc. (APGE) (CIK 0001974640) (APGE)
Apogee Therapeutics, Inc. (APGE) (CIK 0001974640)
Date: March 5, 2024 · CIK: 0001974640 · Accession: 0001104659-24-031034
AI Filing Summary & Sentiment
File numbers found in text: 333-277664
Letter
VIA EDGAR AND EMAIL United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Washington, D.C. 20549 Attention: Chris Edwards Re: Apogee Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-277664)
Dear Mr. Edwards:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Apogee Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to March 7, 2024, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Gibson, Dunn & Crutcher LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Gibson, Dunn & Crutcher LLP, by calling Melanie Neary at (415) 393-8243.
Sincerely,
APOGEE
THERAPEUTICS, INC.
Show Raw Text
CORRESP
1
filename1.htm
March 5, 2024
VIA EDGAR AND EMAIL
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention: Chris Edwards
Re: Apogee Therapeutics, Inc.
Registration
Statement on Form S-1 (File No. 333-277664)
Dear Mr. Edwards:
Pursuant to Rule 461 under the Securities Act of 1933, as amended
(the “Act”), Apogee Therapeutics, Inc. (the “Company”) hereby requests that the effective date
of the above-referenced registration statement (the “Registration Statement”) be accelerated to March 7, 2024,
at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Gibson, Dunn & Crutcher LLP,
request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the
Company acknowledges that it is aware of its obligations under the Act.
Once the Registration Statement is effective, please orally confirm
the event with our counsel, Gibson, Dunn & Crutcher LLP, by calling Melanie Neary at (415) 393-8243.
Sincerely,
APOGEE
THERAPEUTICS, INC.
/s/
Michael Henderson, M.D.
Michael Henderson, M.D.
Chief Executive
Officer
cc:
Jane Pritchett Henderson, Apogee Therapeutics, Inc.
Matthew Batters, Apogee Therapeutics, Inc.
Ryan A. Murr, Gibson, Dunn & Crutcher LLP
Branden C. Berns, Gibson, Dunn & Crutcher LLP
Melanie E. Neary, Gibson, Dunn & Crutcher LLP